Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
World Biotech Regenerative Medical Group Limited maintains a patent portfolio within the Biotechnology & Pharmaceuticals technology area. The company currently has 1 pending office action, which represents the total active workload for its intellectual property assets. This 1 pending office action indicates a focused prosecution strategy where the applicant is pursuing a specific set of claims rather than a broad range of simultaneous applications.
The prosecution landscape for this entity is characterized by 1 distinct examiner and 1 distinct art unit. This concentration means that the entire active portfolio is subject to the review of a single administrative body and the interpretation of 1 distinct examiner. For a practitioner, this lack of diversity in the examining corps allows for a highly targeted communication strategy but increases the impact of the specific preferences held within that 1 distinct art unit.
The busiest examiner for this portfolio is GUSSOW, ANNE, who is currently responsible for the 1 pending office action. Because GUSSOW, ANNE is the only examiner involved in the company's current filings, the success of the portfolio depends on the dialogue with this specific official. The 1 pending office action under GUSSOW, ANNE represents the primary legal hurdle the company must overcome to secure its patent rights in the biotechnology sector.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GUSSOW, ANNE | 1 | 57.9% | +43.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18037003 | SYSTEMS FOR THE DETECTION OF TARGETED GENE VARIATIONS AND VIRAL GENOMES AND METHODS OF PRODUCING AND USING SAME | GUSSOW, ANNE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18037003 | SYSTEMS FOR THE DETECTION OF TARGETED GENE VARIATIONS AND VIRAL GENOMES AND METHODS OF PRODUCING AND USING SAME | GUSSOW, ANNE | — |
| Art Unit | Apps |
|---|---|
| 1683 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18037003 | SYSTEMS FOR THE DETECTION OF TARGETED GENE VARIATIONS AND VIRAL GENOMES AND METHODS OF PRODUCING AND USING SAME | GUSSOW, ANNE | 1683 | §101§103§112 | Non-Final OA | — | Pending | May 15, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialWorld Biotech Regenerative Medical Group Limited has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Anne Gussow has the most, with 1 of World Biotech Regenerative Medical Group Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
